| 000 | 01925 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516234517.0 | ||
| 264 | 0 | _c20150721 | |
| 008 | 201507s 0 0 eng d | ||
| 022 | _a2213-8595 | ||
| 024 | 7 |
_a10.1016/S2213-8587(14)70169-X _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGadelha, Mônica R | |
| 245 | 0 | 0 |
_aPasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. _h[electronic resource] |
| 260 |
_bThe lancet. Diabetes & endocrinology _cNov 2014 |
||
| 300 |
_a875-84 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcromegaly _xdrug therapy |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHuman Growth Hormone _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xanalysis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOctreotide _xtherapeutic use |
| 650 | 0 | 4 |
_aPeptides, Cyclic _xtherapeutic use |
| 650 | 0 | 4 |
_aSomatostatin _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aBronstein, Marcello D | |
| 700 | 1 | _aBrue, Thierry | |
| 700 | 1 | _aCoculescu, Mihail | |
| 700 | 1 | _aFleseriu, Maria | |
| 700 | 1 | _aGuitelman, Mirtha | |
| 700 | 1 | _aPronin, Vyacheslav | |
| 700 | 1 | _aRaverot, Gérald | |
| 700 | 1 | _aShimon, Ilan | |
| 700 | 1 | _aLievre, Kayo Kodama | |
| 700 | 1 | _aFleck, Juergen | |
| 700 | 1 | _aAout, Mounir | |
| 700 | 1 | _aPedroncelli, Alberto M | |
| 700 | 1 | _aColao, Annamaria | |
| 773 | 0 |
_tThe lancet. Diabetes & endocrinology _gvol. 2 _gno. 11 _gp. 875-84 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S2213-8587(14)70169-X _zAvailable from publisher's website |
| 999 |
_c24227169 _d24227169 |
||